A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 5, 2013, Pages 522-528

  Barrett, Yu Chen ^a   Wang, Zhaoqing ^a   Knabb, Robert M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

anticoagulants; factor Xa inhibitors; in vitro diagnostic systems; thrombosis; thrombosis prophylaxis

Indexed keywords

APIXABAN; CALCIUM CHLORIDE; CALCIUM ION; CV 185 022; RAZAXABAN; SODIUM ION; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; BLOOD DONOR; CENTRIFUGATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; HUMAN; HUMAN EXPERIMENT; LABORATORY PERSONNEL; MEASUREMENT ACCURACY; NORMAL HUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; REACTION TIME; REFERENCE VALUE; THROMBOCYTE; THROMBOCYTE COUNT;

ANTICOAGULANTS; FACTOR XA INHIBITORS; IN VITRO DIAGNOSTIC SYSTEMS; THROMBOSIS; THROMBOSIS PROPHYLAXIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; FACTOR XA; HUMANS; PROTHROMBIN TIME; THROMBOSIS;

EID: 84884259241     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612441859     Document Type: Article

References (23)

1. Alexander AH, Singh KP. Inhibition of factor Xa: a potential target for the development of new anticoagulants. Am J Cardiovasc Drugs. 2005 ; 5 (5). 279-290
2. Eriksson BI. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs. 2006 ; 66 (11). 1411-1429
3. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost. 2008 ; 34 (1). 39-57
4. Shantsila E, Lip GYH. Apixaban, an oral, direct inhibitor of activated factor Xa. Curr Opin Invest Drugs. 2008 ; 9 (9). 1020-1033
5. Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM. Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Invest Drugs. 2008 ; 17 (6). 925-937
6. Morell J, Sullivan B, Khalabuda M, McBride BF. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban. J Clin Pharmacol. 2010 ; 50 (9). 986-1000
7. Bates SM, Weitz JI, Serradell N, Rosa E, Bolos J.. Apixaban. Factor Xa inhibitor, anticoagulant. Drugs Future. 2008 ; 33 (4). 293-301
8. Tobu M, Iqbal O, Hoppensteadt D, Neville B, Messmore HL, Fareed J. Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants. Clin Appl Thromb Hemost. 2004 ; 10 (4). 301-309
9. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003 ; 107 (12). 1692-1711
10. Barrett Y, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa is preferable to prothrombin time assay. Thromb Haemost. 2010 ; 104 (6). 1263-1271
11. Swaminathan A, Frost C, Knabb R, Bai SA, Kornhauser D, Garcia RM. Pharmacokinetic and pharmacodynamic characteristics in healthy volunteers of razaxaban, an orally-active, potent, selective inhibitor of factor Xa. Clin Pharm Ther. 2004 ; 76: P6
12. Effects Of Age and Gender on the Single-Dose Pharmacokinetics of BMS-562247 in Healthy Subjects. :
13. Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 2006 ; 23 (2). 312-328
14. Burtis CA, Ashwood ER, Bruns DE Tietz Fundamentals of Clinical Chemistry. 6 th ed. New York. NY: WB Saunders; 2008. New York. NY: WB Saunders ; 2008 :
15. Zweig MH Assessment of the Clinical Accuracy of Laboratory Tests Using Receiver Operating Characteristic (ROC) Plots; Approved Guideline, GP10-A. Clinical and Laboratory Standards Institute: Wayne, PA ; 2001 :
16. Frost C, Yu Z, Nepal S, et al. Apixaban, an oral direct, factor Xa inhibitor: multiple ascending-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J Thromb Haemost. 2007 ; 5 (suppl 2). P-M-664
17. Clinical Hematology and Fundamentals of Hemostasis. - 3rd ed.. Harmening DM, ed. F. A Davis company: Philadelphia ; 1997: 481-506.
18. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008 ; 6 (5). 820-829
19. Frost C, Yu Z, Moore K, Nepal S, et al. Apixaban, an oral direct, factor Xa inhibitor: single-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J Thromb Haemost. 2007 ; 5 (suppl 2). P-M-665
20. Smith SA, Morrissey JH. Thromboplastin composition affects the sensitivity of prothrombin time (PT) clotting tests to direct factor Xa inhibitors. Blood. 2007 ; 110: 928
21. Testa S, Morstabilini G, Fattorini A, Galli L, Denti N, D'Angelo A. Discrepant sensitivity of thromboplastin reagents to clotting factor levels explored by the prothrombin time in patients on stable oral anticoagulant treatment: impact on the international normalized ratio system. Haematologica. 2002 ; 87 (12). 1265-1273
22. Lottin L, Woodhams BJ, Saureau M, et al. The clinical relevance of the citrate effect on International Normalized Ratio determinations depends on the reagent and instrument combination used. Blood Coagul Fibrinolysis. 2001 ; 12 (5). 399-404
23. Collection, Transport, and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays. Approved Guideline - 3rd ed. Wayne, PA: CLSI ; 1998 :